Moderna
MRNA
903 hedge funds and large institutions have $28.1B invested in Moderna in 2024 Q1 according to their latest regulatory filings, with 110 funds opening new positions, 330 increasing their positions, 298 reducing their positions, and 79 closing their positions.
39% more first-time investments, than exits
New positions opened: 110 | Existing positions closed: 79
22% more call options, than puts
Call options by funds: $1.61B | Put options by funds: $1.32B
11% more repeat investments, than reductions
Existing positions increased: 330 | Existing positions reduced: 298
10% more capital invested
Capital invested by funds: $25.6B → $28.1B (+$2.51B)
2% more funds holding
Funds holding: 884 → 903 (+19)
1.32% more ownership
Funds ownership: 67.45% → 68.77% (+1.3%)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$726M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$517M |
| 3 |
Morgan Stanley
New York
|
+$111M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$83.1M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$78.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Coatue Management
New York
|
-$326M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$163M |
| 3 |
JP Morgan Chase
New York
|
-$110M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$101M |
| 5 |
Goldman Sachs
New York
|
-$62.7M |
MRNA Hedge Fund Activity: Q1 2024 in Review
903 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q1 2024, worth a combined $28.1B — up 9.8% from $25.6B a quarter earlier.
Buyers outnumbered sellers: 110 funds opened new MRNA positions and 79 closed out — a net gain of 31 holders — while 330 added to existing stakes and 298 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $726M. The largest seller was Coatue Management, exiting entirely with an estimated $326M sold.
- 903 institutional investors held Moderna (MRNA) as of Q1 2024, up from 884 in Q4 2023.
- Funds reported $28.1B of Moderna stock for Q1 2024, up 9.8% quarter-over-quarter.
- 110 funds opened new Moderna positions in Q1 2024 and 79 closed out, a net change of +31 holders.
- The largest Moderna buyer in Q1 2024 was Fidelity Investments, an estimated $726M added.
- The largest Moderna seller in Q1 2024 was Coatue Management, an estimated $326M sold.
Based on aggregated 13F filings for Q1 2024.